Showing "Biogen Incorporated" Clinical Trials, all 5

To determine the maximal safe daily dose of BG8962 (rCD4) which can be administered by
continuous subcutaneous infusion (CSCI) over 24 hours; to determine the pharmacokinetics of
BG8962 when it is administered by intramuscular and subcutaneous routes; and to look for
dose related antiviral activity determined by quantitation of infectious HIV peripheral
blood leukocytes (PBLs) and plasma, and by monitoring the blood levels of viral p24 antigen
(when present), CD4+ T-cells, and ...

Previous Biogen studies have provided experience with the tolerability, immunogenicity, and
efficacy of a single and multiple 12-week courses of therapy of alefacept. At this stage,
experience in larger studies, as well as the FDA-approved labeling, is confined to treatment
courses of 12 weeks. The purpose of the present study is to offer an extended course of
therapy with alefacept.

The purpose of this study is to see if we can find a new way to test how certain Multiple
Sclerosis (MS) medications work in the body and to better understand how the medicines
change certain substances (cells) found in the immune (protective) system.
Blood test will be drawn by doing the following:
- Use a new method called the "Immuknow®" Test to see if this method will help to better
understand how MS medicines work.
- Measure certain levels of immune ce...

This is an observational, exposure-registration and follow-up study, which will be conducted
in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor
pregnant subjects and fetuses inadvertently exposed to AVONEX® and to detect any potential
increase in the risk of major birth defects. It is also designed to detect any potential
increase in the risk of spontaneous pregnancy loss. The AVONEX® Pregnancy Exposure Registry
is sponsored by Bioge...